# Julian Weldon Adlard

List of Publications by Year
in descending order



| 55 | 6,648 | 186209 | 149623 |
|---|---|---|---|
| papers | citations | 28 h-index | 56 g-index |

| 56 | 56 | 56 | 10225 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA - Journal of the American Medical Association, 2017, 317, 2402. | 3.8 | 1,898 |
| 2 | Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE. Journal of the National Cancer Institute, 2013, 105, 812-822. | 3.0 | 753 |
| 3 | Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347. | 3.8 | 390 |
| 4 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691. | 9.4 | 356 |
| 5 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778. | 9.4 | 289 |
| 6 | Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. European Urology, 2015, 68, 186-193. | 0.9 | 279 |
| 7 | Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685. | 0.8 | 270 |
| 8 | Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212. | 1.5 | 244 |
| 9 | Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620. | 1.1 | 224 |
| 10 | Tumour risks and genotypeâ€“phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD. Journal of Medical Genetics, 2018, 55, 384-394. | 1.5 | 177 |
| 11 | Comprehensive Study of the Clinical Phenotype of GermlineBAP1Variant-Carrying Families Worldwide. Journal of the National Cancer Institute, 2018, 110, 1328-1341. | 3.0 | 164 |
| 12 | Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250. | 0.8 | 152 |
| 13 | Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. European Urology, 2020, 77, 24-35. | 0.9 | 124 |
| 14 | Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genetics, 2013, 9, e1003173. | 1.5 | 105 |
| 15 | Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419. | 2.2 | 97 |
| 16 | Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15. | 2.2 | 88 |
| 17 | Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666. | 1.1 | 82 |
| 18 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110. | 2.2 | 71 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321. | 1.4 | 68 |
| 20 | Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416. | 2.2 | 57 |
| 21 | DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256. | 1.5 | 47 |
| 22 | Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. American Journal of Human Genetics, 2018, 103, 3-18. | 2.6 | 46 |
| 23 | MLH1 â^'93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. International Journal of Cancer, 2008, 123, 2456-2459. | 2.3 | 44 |
| 24 | Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2020, 22, 8. | 2.2 | 41 |
| 25 | Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638. | 0.4 | 39 |
| 26 | Robust Diagnostic Genetic Testing Using Solution Capture Enrichment and a Novel Variantâ€Filtering Interface. Human Mutation, 2014, 35, 434-441. | 1.1 | 38 |
| 27 | Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. American Journal of Obstetrics and Gynecology, 2021, 225, 51.e1-51.e17. | 0.7 | 34 |
| 28 | Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectrum, 2018, 2, pky023. | 1.4 | 33 |
| 29 | Cas9-based enrichment and single-molecule sequencing for precise characterization of genomic duplications. Laboratory Investigation, 2020, 100, 135-146. | 1.7 | 33 |
| 30 | Thalidomide in the treatment of cancer. Anti-Cancer Drugs, 2000, 11, 787-791. | 0.7 | 32 |
| 31 | Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747. | 1.4 | 32 |
| 32 | Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364. | 3.0 | 30 |
| 33 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38. | 2.3 | 28 |
| 34 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61. | 2.2 | 26 |
| 35 | A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370. | 1.1 | 23 |
| 36 | Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers. Breast Cancer Research, 2012, 14, R63. | 2.2 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Increasing Evidence for the Association of Breast Implant-Associated Anaplastic Large Cell Lymphoma and Li Fraumeni Syndrome. Case Reports in Genetics, 2019, 2019, 1-5. | 0.1 | 20 |
| 38 | Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192. | 2.9 | 19 |
| 39 | A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078. | 5.8 | 19 |
| 40 | Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122. | 3.0 | 19 |
| 41 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134. | 1.1 | 18 |
| 42 | The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737. | 1.1 | 16 |
| 43 | Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. Genetics in Medicine, 2018, 20, 1575-1582. | 1.1 | 15 |
| 44 | Additional loss of MSH2 and MSH6 expression in sporadic deficient mismatch repair colorectal cancer due to MLH1 promoter hypermethylation. Journal of Clinical Pathology, 2019, 72, 443-447. | 1.0 | 14 |
| 45 | Lymphocyte Telomere Length Is Long in BRCA1 and BRCA2 Mutation Carriers Regardless of Cancer-Affected Status. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1018-1024. | 1.1 | 13 |
| 46 | Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801. | 1.1 | 10 |
| 47 | Histopathology of melanocytic lesions in a family with an inherited <scp>BAP1</scp> mutation. Journal of Cutaneous Pathology, 2016, 43, 287-289. | 0.7 | 10 |
| 48 | SDHC phaeochromocytoma and paraganglioma: A UKâ€wide case series. Clinical Endocrinology, 2022, 96, 499-512. | 1.2 | 7 |
| 49 | Prostate Cancer Risk by BRCA2 Genomic Regions. European Urology, 2020, 78, 494-497. | 0.9 | 6 |
| 50 | Characterization and Genomic Localization of a SMAD4 Processed Pseudogene. Journal of Molecular Diagnostics, 2017, 19, 933-940. | 1.2 | 5 |
| 51 | Increased Sensitivity of Diagnostic Mutation Detection by Re-analysis Incorporating Local Reassembly of Sequence Reads. Molecular Diagnosis and Therapy, 2017, 21, 685-692. | 1.6 | 4 |
| 52 | Long-read nanopore sequencing enables accurate confirmation of a recurrent PMS2 insertionâ€“deletion variant located in a region of complex genomic architecture. Cancer Genetics, 2021, 256-257, 122-126. | 0.2 | 4 |
| 53 | Evaluation of tumour surveillance protocols and outcomes in von Hippel-Lindau disease in a national health service. British Journal of Cancer, 2022, 126, 1339-1345. | 2.9 | 4 |
| 54 | Multiple primary cancers (renal papillary, lymphoma and teratoma) and hepatic cysts in association with a pathogenic germline mutation in the MET gene. Familial Cancer, 2021, 20, 81-83. | 0.9 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Homozygosity for the pathogenic RET hotspot variant p.Cys634Trp: A consanguineous family with MEN2A. European Journal of Medical Genetics, 2021, 64, 104141. | 0.7 | 3 |